Enriqueta Felip, MD, PhD
Enriched profileHead of the Thoracic and Head and Neck Cancer Unit, Oncology Department, Vall d'Hebron University Hospital (also described as Section Head of the Medical Oncology Service); Group Leader, Thoracic Tumors & Head and Neck Cancer Group, VHIO · Vall d'Hebron Institute of Oncology (VHIO)
Enriqueta Felip is Head of the Thoracic and Head and Neck Cancer Unit, Oncology Department, Vall d'Hebron University Hospital (also described as Section Head of the Medical Oncology Service); Group Leader, Thoracic Tumors & Head and Neck Cancer Group, VHIO at Vall d'Hebron Institute of Oncology (VHIO). OpenAlex indexes 1,460 publications with 110,546 citations (h-index 129); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Enriqueta Felip is Head of the Thoracic and Head and Neck Cancer Unit, Oncology Department, Vall d'Hebron University Hospital (also described as Section Head of the Medical Oncology Service) at Vall d'Hebron Institute of Oncology (VHIO) / Vall d'Hebron University Hospital, Barcelona, Spain. The public record shows 1,460 publications with 110,546 citations (h-index 129), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. It also documents an investigator role on 8 registered clinical trials.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 8 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 594.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
Public positions
sourced statements on record- Advocated (as SEOM President, 2021) for equitable access to genetic counseling
molecular diagnostics, and personalized treatment strategies across Spain's public oncology system
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Vall d'Hebron Institute of Oncology
Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Sponsor: Pierre Fabre Medicament
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
Journal of clinical oncology
Article2026 - Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.
Future oncology (London, England)
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer6,620 citations2018
- 03
- 04Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer6,233 citations2015
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Enriqueta-Felip
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/enriquetafelip
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/Ck-qAwlDUwt
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/reel/C4Q-6lMtB-Z
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/posts/vall-d'hebron-institut-d'oncologia_la-dra-enriqueta-felip-ha-rebut-el-xi-premi-activity-6927515196957581312-mUkQ
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hospital.vallhebron.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hospital.vallhebron.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hospital.vallhebron.com ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →esmo.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
Awards & honors
honors on the public record- Clarivate Web of Science Highly Cited Researcher (Clinical Medicine)
2019, 2020, 2021, and confirmed again in later independent listings for 2023, 2024, and 2025
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
- Premi Vanguardia de la Ciència (Vanguardia Science Prize) 2022 (XI edition)
for IMpower010 lung cancer immunotherapy research
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vallhebron.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hospital.vallhebron.com ↗
- Professor of Medicine
Universitat de Vic (UVic-UCC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vhio.net ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ecancer.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clinical-conversations-podcast.nejm.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.